JNJ-440 not checked
Alios Biopharma Inc. · JNJ-64530440 or ALS-003440
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “JNJ-440 will be administered as oral tablets in Parts 1, 2 and 3. JNJ-440 may be provided as oral solution in a cohort in Part 1.”In the company’s words, NCT03439488 on ClinicalTrials.gov
- Tested for
- Chronic Hepatitis B
- Main trialPhase 1
- “The purpose of this study is to evaluate the safety and tolerability of JNJ-440 in healthy and Chronic Hepatitis B (CHB) participants after single and multiple doses; and to evaluate the pharmacokinetic (PK) of JNJ-440 in healthy participants and in CHB participants following single and multiple dose regimens, administered alone (healthy participants and CHB participants).”In the company’s words, NCT03439488 on ClinicalTrials.gov
- Other names
- JNJ-64530440 or ALS-003440
Other drugs for Chronic Hepatitis B
- GST-HG141Fujian Akeylink Biotechnology Co., Ltd. · Phase 3
- AHB-137Ausper Biopharma Co., Ltd. · Phase 3
- ZM-H1505RShanghai Zhimeng Biopharma, Inc. · Phase 3
- TQA3605Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Phase 3
- Tenofovir DFGilead (Kite) · Phase 3
- HT-101Suzhou HepaThera Biotech Co., Ltd. · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Completed | 10 Oct 2019 | A Study of Orally Administered JNJ-440 to Evaluate the Safety, Tolerability, and Pharmacokinetics After Single Ascending Doses Including Food Effect Evaluation; After Multi-Day Dosing in Healthy Participants; and After Multiple (Ascending) Doses in Participants With Chronic Hepatitis B |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026